Laboratory testing of stool samples for toxigenic Clostridium
|
|
- Charla Melton
- 6 years ago
- Views:
Transcription
1 Comparison of Analytical and Clinical Performance of Three Methods for Detection of Clostridium difficile P. Rocco LaSala, MD; Annika M. Svensson, MD, PhD; Amin A. Mohammad, PhD; Peter L. Perrotta, MD N Context. Diagnostic laboratory testing for Clostridium difficile infection has undergone considerable and rapid evolution during the last decade. The ideal detection method(s), which should exhibit high analytical and clinical sensitivity and specificity, remains undefined. Objective. We sought to evaluate the analytical and clinical performance characteristics of three methods for the laboratory detection of C difficile. Design. This study used 114 consecutive stool samples to compare three methods of C difficile detection: an enzyme immunoassay (EIA) for toxins A/B, a lateral flow membrane immunoassay for glutamate dehydrogenase (GDH), and a qualitative real-time polymerase chain reaction (PCR) assay. Medical records of all patients having $1 positive test result were reviewed to estimate the clinical likelihood of C difficile infection. Results. Based upon laboratory result consensus values, analytical sensitivity was significantly higher for GDH (94%) and PCR (94%) assays than for toxin EIA (25%). Analytical specificity was significantly higher for PCR (100%) and EIA (100%) than for GDH assay (93%). In contrast, assay performance based upon clinical probability of C difficile infection suggested lower discriminatory power (ie, clinical specificity) of the more analytically sensitive methods. Conclusions. Higher rates of C difficile detection will be realized upon implementation of GDH assay and/or real-time PCR based testing algorithms than by testing with EIA alone. Further study is required to elucidate potential downstream costs for higher detection rates. (Arch Pathol Lab Med. 2012;136: ; doi: / arpa oa) Laboratory testing of stool samples for toxigenic Clostridium difficile infection (CDI) has evolved considerably during the past 3 decades. Cytotoxicity to fibroblast monolayers, a key feature that helped to implicate the organism as an etiological factor in colitis, remained the in vitro diagnostic gold standard for many years. 1 Due largely to its complexity and long turnaround time, the cytotoxicity assay was superseded by various toxin enzyme immunoassay (EIA) formulations. While those assays demonstrate favorable performance characteristics compared to one another or to the cytotoxicity assay, 2 recent evidence suggests their sensitivity is unacceptably low compared to techniques such as anaerobic toxigenic culture assay. 3 As a result, alternative diagnostic methods have been proposed, including the use of toxigenic culture itself, two-step algorithms incorporating glutamate dehydrogenase (GDH) common antigen assays, and more recently, nucleic acid amplification tests (eg, polymerase chain reaction [PCR]). The purpose of this study was to evaluate in parallel a few of these methods (ie, EIA, real-time PCR, and GDH assay) in order to Accepted for publication July 26, From the Clinical Laboratories, Department of Pathology, Robert C. Byrd Health Science Center, West Virginia University Hospitals, Morgantown. Dr Mohammad is currently with The Texas A&M University System Health Science Center, Temple. The authors have no relevant financial interest in the products or companies described in this article. Reprints: P. Rocco LaSala, MD, Department of Pathology, West Virginia University, WVUH Clinical Labs, Box 8009, One Medical Center Dr, Morgantown, WV ( plasala@hsc.wvu.edu). assess their analytical and logistical performances and the potential impact of each method on patient management at a 500-bed regional academic medical center. MATERIALS AND METHODS Between February 18, 2010, and March 19, 2010, consecutive, nonformed stool samples submitted Monday through Friday to West Virginia University Hospital (WVUH) Clinical Laboratories, Morgantown, West Virginia, for C difficile toxin testing by routine EIA (Wampole C difficile Tox A/B; Inverness Medical Diagnostics, Princeton, New Jersey) were also tested in parallel with the GeneXpert C difficile real-time PCR assay (Cepheid Diagnostics, Sunnyvale, California) and a rapid lateral flow immunochromatographic GDH assay (C difficile Quik Chek Complete; Techlab, Blacksburg, VA). All three assays were performed according to the manufacturers instructions and included appropriate controls. All discrepant stool samples with sufficient residual material maintained at 220uC were sent for supplemental testing at two outside laboratories using different commercially available PCR assays (GeneXpert C difficile/epi assay [Cepheid Diagnostics, Sunnyvale, California] and Gene- Ohm Cdiff assay [BD Diagnostics, Franklin Lakes, New Jersey]). Control strains for all testing included toxigenic C difficile American Type Culture Collection (ATCC) strain , Clostridium perfringens ATCC strain 13124, and Clostridium sordelli ATCC strain True positive results were defined as those found to be positive by two or more in-house or reference laboratory molecular assays. Following approval by local institutional review board, a retrospective review of electronic medical records was performed by a single author (P.R.L.) who was blinded to study findings, with the exception of EIA results, which had already been reported in patients charts. The following parameters were assessed for purposes of CDI categorization: (1) exposure to Arch Pathol Lab Med Vol 136, May 2012 Laboratory Detection of C difficile LaSala et al 527
2 Results distribution is shown for 24 positive stool samples submitted for C difficile testing by polymerase chain reaction (PCR) (GeneXpert; Cepheid Diagnostics, Sunnyvale, California), glutamate dehydrogenase (GDH) common antigen (Quik Chek Complete; Techlab, Blacksburg, Virginia), and toxin enzyme immunoassay (EIA) (Wampole C difficile Tox A/B; Inverness Medical Diagnostics, Princeton, New Jersey). antibiotics within 6 weeks preceding testing; (2) documented diarrhea (of any quantity or duration) within 7 days of specimen collection; (3) leukocytosis ( white blood cells [WBC]/mL) within 1 day of specimen collection; (4) a history of CDI (with or without laboratory confirmation); (5) prior or subsequent treatment for CDI; and (6) $2 toxin EIA tests ordered on different days. Probability of CDI was defined as unlikely, possible, or likely with fulfillment of #1, 2, or $3 of these parameters, respectively; if $2 parameters could not be determined from available records, probability of CDI was categorized as unknown. RESULTS During the study period, WVUH clinical laboratories received and processed 114 consecutive unformed stool samples that were included for analysis. Among the total, 87 samples were found to be negative by all three assays. Three additional samples were unresolved by PCR (ie, duplicate invalid results) and negative by both of the other methods. The remaining 24 samples demonstrated $1 positive test result (Figure). Only 3 of 24 samples (12%) were positive by all three methods. The GDH assay detected analyte in 22 of 24 samples, of which 7 samples (33%) were positive only by GDH assay. The PCR assay detected analyte in 16 of 24 samples, of which only 2 samples (12%) were positive exclusively by PCR. The toxin EIA detected analyte in only 4 of 24 samples, none of which was positive by EIA alone. For discrepant samples, residual frozen material was forwarded to two reference laboratories for supplementary PCR testing, which confirmed initial GeneXpert PCR results in all specimens tested. Under the assumption that samples unavailable for referral testing would have been similarly confirmed, and excluding 1 sample found positive only by in-house PCR, true positive and true negative values were assigned based on assay consensus results (ie, $2 tests had positive results) (Table 1). Using these data, sensitivity, specificity, and positive and negative predictive values (PPVs and NPVs, respectively) were calculated for each detection method (Table 2). A chart review was conducted for all 22 patients who had $1 positive test result (1 patient had 3 samples with positive results) (Table 3). The number of positive results was the same for both males and females. Mean age was 50 years old, and the cohort included 4 pediatric-aged patients, 2 of whom were less than 1 year of age. Less than half the patients with available WBC counts had evidence of leukocytosis, and nearly one-fourth (all outpatients) had no concomitant orders for blood counts. Of 18 patients with available treatment records, all had prior exposure to antibiotics within the preceding 42 days. Only 7 of 18 patients received directed therapy for CDI based on EIA results and/or clinical impression, while an additional 4 patients received intravenous vancomycin and/or metronidazole therapy for another indication (eg, intraabdominal abscess). More than one-third (7 of 18) of patients with available treatment records received no directed or incidental therapy for C difficile activity (ie, vancomycin or metronidazole). Clinical and laboratory parameters were then compared among patient subsets according to the estimated likelihood of clinical CDI (Table 4). As expected, features supporting a diagnosis of CDI were more prevalent among those patients with a high likelihood of diagnosis than those with a possible or unlikely diagnosis. Analysis of individual or collective C difficile laboratory results revealed little appreciable distinction among the three diagnostic likelihood categories (Table 4). That is, while patients with high disease probability had results that were uniformly or frequently positive by GDH and PCR assays (suggesting high clinical sensitivity), results from these same methods were also positive in a large proportion of patients with lower estimated likelihood of CDI, based on our clinical model (suggesting low clinical specificity). Although EIA demonstrated good clinical specificity (ie, few positive results among patients with low likelihood of disease), it was not especially useful for detecting patients with high disease probability (suggesting low clinical sensitivity). Furthermore, true positive results, as defined by the laboratory test consensus standard ($2 tests with positive results), showed little association with any particular diagnostic likelihood group (Table 4). COMMENT It has recently become apparent that widespread use of EIA by clinical laboratories for detecting C difficile exotoxin(s) may be insufficient for establishing a diagnosis of CDI. Several reports have documented poor analytical sensitivity of toxin immunoassays in comparison to toxigenic culture and/or various PCR-based assays The present study supports those findings. Coupled with the fact that many laboratories still use the relatively low-cost toxin EIA as the primary method for laboratory diagnosis, 11,12 medical providers may frequently face the decision whether to initiate therapy in the absence of laboratory confirmation or to repeat laboratory tests. The former choice is recommended only for cases of severe or complicated disease 13 and is not consistent with recent case definitions. 14,15 The latter approach is hampered by 528 Arch Pathol Lab Med Vol 136, May 2012 Laboratory Detection of C difficile LaSala et al
3 Table 1. Results by Assay of 24 Specimens Having $1 Positive Result for C difficile Sample No. GDH PCR Toxin EIA Reference Laboratory Result a True Positive b Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N N N N N N ND c Y Abbreviations: EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; ND, not determined; PCR, polymerase chain reaction. a Reference laboratory methods included GeneXpert C difficile/epi assay (Cepheid Diagnostics, Sunnyvale, California) and GeneOhm Cdiff assay (BD Diagnostics, Franklin Lakes, New Jersey). Testing was performed with stool aliquots stored and shipped at 220uC. b As determined by laboratory test result consensus. c Sample was unavailable for supplemental testing; result status was not determined. successive decreases in PPV with each sequential test, as illustrated by Peterson and Robicsek. 16 Improvement of immunoassay formats that detect C difficile-specific GDH marked a potential diagnostic advancement with minimal increases in assay cost compared to that of toxin EIAs. Ticehurst and colleagues 17 were the first to report high NPVs for that test, and many studies have upheld their conclusion that it can sufficiently exclude carriage of C difficile Clinical specificity and PPV of the GDH assay are negatively impacted, however, by the test s inherent reactivity against both toxigenic and nontoxigenic strains, as corroborated by the present study (Tables 2 and 4). Hence, GDH-positive samples require follow-up testing to determine whether they harbor organisms capable of toxin production. The need for this second-step test to exhibit reasonable sensitivity and turnaround time, in addition to specificity, restricts the utility of toxigenic culture, toxin EIA, and cell cytotoxicity assays in this role. Recent investigations have focused on real-time PCR as a candidate for GDH screen confirmation. Using the same GDH assay described here, Sharp et al 21 and Swindells et al 8 reported excellent performance characteristics of a two-step GDH-PCR algorithm. They observed,100% sensitivity of the GDH screen component compared with toxigenic culture and/or PCR, as well as excellent correlation between second-step PCR testing and toxigenic culture results. Others have noted somewhat lower sensitivity (,85% 90%) for GDH screening assays than for universal PCR and/or toxigenic culture. 4,5,22 Interestingly, one report highlighted different performance characteristics for GDH algorithms depending upon bacterial ribotype. 9 It remains unclear whether differences in published values of GDH sensitivity are due to regional strain variation, variable performance characteristics of molecular assays, differences in reference comparator methods (eg, culture techniques), or perhaps other causes; and debate persists regarding the benefits of two-step algorithms incorporating GDH assay (eg, offering significantly decreased costs) versus universal PCR testing. 23 The present study substantiates the reported high sensitivity values for GDH (94%) and PCR (94%), as well as their excellent NPVs (99%). The present study further demonstrates that a substantial increase in the rate of C difficile detection would be realized upon implementation of universal PCR or a GDH-PCR algorithm in comparison to testing by toxin EIA alone. This investigation also incorporated a retrospective clinical assessment that revealed several interesting findings. Foremost among the findings was the absence of any documentation of diarrhea in more than one-third of patients whose records were accessible. In their prospective study, Peterson and colleagues 15 found a similarly high proportion (39%) of potential CDI episodes that did not meet criteria for diarrhea (ie, $3 loose stools in 1 day). The primary limitation of the current approach was its retrospective nature, inasmuch as the absence of documented diarrhea cannot be interpreted definitively as a documented absence; yet the lack of mention altogether in such a large proportion of cases is noteworthy given the fact that diarrhea is the most common underlying feature of CDI. 1 Assuming that our clinical model is accurate despite other limitations (eg, inherent bias), inclusion of patients with low pretest probability could potentially account for the poor correlation observed between analytical and clinical performances of the laboratory assays. Table 4 suggests that assays with high clinical Table 2. Performance Characteristics of Three Laboratory Assays for Detection of C difficile Using Assay Consensus as the Reference Method Characteristic GDH Toxin EIA PCR a % of sensitivity (95% CI) 94 (70 99) b 25 (10 50) b 94 (70 99) b % of specificity (95% CI) 93 (87 97) c 100 (95 100) c 100 (95 100) c NPV % (95% CI) 99 (94 100) 89 (82 94) 99 (94 100) PPV % (95% CI) 69 (47 84) 100 (45 100) 100 (77 100) Abbreviations: CI, confidence interval; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; NPV, negative predictive value; PCR, polymerase chain reaction; PPV, positive predictive value. a Calculations excluded 3 indeterminate PCR results. b Significant differences (P,.001) were found between GDH and EIA and between PCR and EIA results. c Significant differences (P 5.01) were found between EIA and GDH and between PCR and GDH assay results. Arch Pathol Lab Med Vol 136, May 2012 Laboratory Detection of C difficile LaSala et al 529
4 Table 3. Overall Clinical Features of 22 Patients Testing Positive by $1 Laboratory Assay for Detection of C difficile Parameter Number % of total Male:Female ratio 11:11 Patient age (years) # Patients with history of antibiotic 18/18 patients a 100 exposure Described nature of diarrhea Severe and/or persistent 9 41 Documented but not categorized 4 18 Not recorded in medical record 7 32 Outpatient clinic note not 2 9 available WBC count (WBC/mL) Count not performed 5 23 Mean number of toxin EIAs 2 (range, 1 5) History of CDI 2 9 Treatment for CDI Targeted oral therapy 7 32 Nontargeted intravenous therapy 4 18 Unknown a 4 18 None 7 32 Probability of CDI Likely 9 41 Possible 5 23 Unlikely 4 18 Unknown 4 18 Abbreviations: CDI, C difficile infection; EIA, enzyme immunoassay; WBC, white blood cell. a Four outpatients had insufficient antibiotic prescription data to determine past exposure or treatment for CDI. sensitivity (ie, few negative results among patients with high likelihood of disease) may exhibit reduced clinical specificity (ie, many positive results among patients with low likelihood of disease). Conversely, high clinical specificity seemed to be achieved at the cost of reduced clinical sensitivity. Interestingly, among the 18 patients in this study with available treatment records and $1 positive C difficile test result, 7 patients received no therapy for CDI, including 1 likely and 3 probable cases (based on likelihood estimates) and 3 true positives (based upon laboratory consensus results). Given that antibiotic-associated diarrhea may subside following discontinuation of the inciting antibiotic alone, 24 this observation may not be especially remarkable. Had a more analytically sensitive assay been in place during the study period, however, many of these patients would likely have received directed antimicrobial therapy for CDI. Further investigation of the direct and indirect economic, epidemiological, and clinical consequences of higher detection rates and resulting impact on therapeutic interventions is warranted. Expansion of our observations, particularly under circumstances where pretest probabilities can be firmly assessed, will be required to determine the overall benefits and costs of implementing more analytically sensitive assays for C difficile detection. Chart review also highlighted instances of potential misuse of laboratory resources. Two patients with a history of CDI and prior positive laboratory results reported 6 and 19 days earlier, respectively, had $1 positive test result. Recent consensus reports point out that a test for cure is not indicated 13 and that an additional positive [laboratory] result... performed on a specimen collected #2 weeks after the last specimen that tested positive represents continuation of the same CDI case. 14 Additionally, 2 patients with positive results were noted to be,1 year of age. Given the high rates of C difficile colonization documented during infancy and early childhood, 25 the clinical specificity of CDI diagnostic assays applied to this population has been called into question. 26 Table 4. Clinical and Laboratory Features of 22 Patients with $1 Laboratory Test Result Positive for C difficile Listed by CDI Probability Parameter No. of Patients in the Likelihood Group/Total Number of Patients a Likely (n = 9) Possible (n = 5) Unlikely (n = 4) Unknown (n = 4) Clinical feature Documented diarrhea 9/9 1/4 0/4 2/2 Leukocytosis 6/8 2/4 0/4 0/1 Treated for CDI 6/7 2/5 b 2/4 b 1/2 History of CDI 2/9 0/5 0/4 0/4 Mean no. of EIAs performed Positive test result GDH 9/9 4/5 4/4 3/4 Toxin EIA 3/9 0/5 0/4 1/4 PCR 7/9 2/5 4/4 1/4 Combined laboratory results 3 positive test results 3/9 0/5 0/4 0/4 $2 positive test results 7/9 1/5 4/4 1/4 Abbreviations: CDI, C difficile infection; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; PCR, polymerase chain reaction. a For some clinical parameters, the sum of denominators does not total 22 patients because data were unavailable in some patient records. b Four patients who received nondirected therapy. 530 Arch Pathol Lab Med Vol 136, May 2012 Laboratory Detection of C difficile LaSala et al
5 This study suggests that both GeneXpert C difficile PCR and the Quik Chek GDH immunoassay demonstrate acceptably high analytical and clinical sensitivity values for diagnosis of CDI at our institution. Analytical specificity of PCR is also high, suggesting that it could serve as an acceptable confirmatory test for positive GDH screening. However, the clinical specificity of both of these assays may be reduced, particularly in scenarios where pretest probability is low and/or asymptomatic colonization is high. Finally, diagnostic reliance on toxin EIA appears to be limited by its poor sensitivity. References 1. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S12 S Musher DM, Manhas A, Jain P, et al. Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. J Clin Microbiol. 2007;45(8): Crobach MJ, Dekkers OM, Wilcox MH, Kuijper MJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15(12): Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdb, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol. 2009; 47(10): Larson AM, Fung A, Fang FC. Evaluation of tcdb real-time PCR in a threestep diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol. 2010;48(1): Sloan LM, Duresko BJ, Gustafson DR, Rosenblatt JE. Comparison of realtime PCR for detection of the tcdc gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol. 2008; 46(6): Stamper PD, Babiker W, Alcabasa R, et al. Comparison of a commercial real-time PCR assay for tcdb detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol. 2009;47(2): Swindells J, Brenwald N, Reading N, Oppenheim B. Evaluation of diagnostic tests for Clostridium difficile infection. J Clin Microbiol. 2010;48(2): Tenover FC, Novak-Weekley S, Woods CW, et al. Impact of strain types on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol. 2010;48(10): Wren MWD, Sivapalan M, Kinosn R, Shetty NP. Laboratory diagnosis of Clostridium difficile infection. An evaluation of tests for faecal toxin, glutamate dehydrogenase, lactoferrin and toxigenic culture in the diagnostic laboratory. Br J Biomed Sci. 2009;66(1): Cooke RPD, Collins J, Galloway A, Holland D, Trigg G. Audit of the laboratory diagnosis of Clostridium difficile infection in the UK. J Hosp Infect. 2010;75(4): Microbiology Resource Committee, Proficiency Test Survey, Bacteriology D-A, Northfield, IL: College of American Pathologists; Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5): McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007;28(2): Peterson LR, Manson RU, Paule SM, et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Dis. 2007;45(9): Peterson LR, Robicsek A. Does my patient have Clostridium difficile infection? Ann Intern Med. 2009;151(3): Ticehurst JR, Aird DZ, Dam LM, Borek AP, Hargrove JT, Carroll KC. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol. 2006;44(3): Gilligan PH. Is a two-step glutamate dehyrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile? J Clin Microbiol. 2008;46(4): Quinn CD, Sefers SE, Babiker W, et al. Diff Quik Chek complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens. J Clin Microbiol. 2010;48(2): Reller ME, Lema CA, Perl TM, et al. Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol. 2007;45(11): Sharp SE, Ruden LO, Pohl JC, Hatcher PA, Jayne LM, Ivie WM. Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of Clostridium difficile disease. J Clin Microbiol. 2010;48(6): Novak-Weekley SM, Marlowe EM, Miller JM, et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol. 2010;48(3): Wilcox MH, Planche T, Fang FC, Gilligan P. What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol. 2010;48(12): Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346(5): Jangi S, Lamont JT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr. 2010; 51(1): Bryant K, McDonald LC. Clostridium difficile infections in children. Pediatr Infect Dis J. 2009;28(2): Arch Pathol Lab Med Vol 136, May 2012 Laboratory Detection of C difficile LaSala et al 531
Clinical Microbiology, Cork University Hospital, Wilton, Cork, Ireland; 3 Dept. of Clinical
A prospective, three-centre study to determine the efficacy of the EntericBio realtime C. difficile Assay (EBCD) for the detection of toxigenic C. difficile in stool samples. B. Lucey 1*, L. Blake 2, M.
More informationScience. Evaluation of Glutamate Dehydrogenase Immunoassay Screening with Toxin Confirmation for the Diagnosis of Clostridium difficile Infection
Evaluation of Glutamate Dehydrogenase Immunoassay Screening with Toxin Confirmation for the Diagnosis of Clostridium difficile Infection Steve Miller, MD, PhD, 1 * Arun Wiita, MD, PhD, 1 Carolyn Wright,
More informationEvaluation of the C.DIFF Quik Chek Complete assay, a new GDH & A/B toxin
JCM Accepts, published online ahead of print on 7 April 2010 J. Clin. Microbiol. doi:10.1128/jcm.00129-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationDiscovering the Optimal Approach to Diagnosing Clostridium difficile Infection (CDI) PRESENTED BY: NATHAN A. LEDEBOER, PHD, D(ABMM)
Discovering the Optimal Approach to Diagnosing Clostridium difficile Infection (CDI) PRESENTED BY: NATHAN A. LEDEBOER, PHD, D(ABMM) PROFESSOR OF PATHOLOGY AND VICE CHAIR DEPARTMENT OF PATHOLOGY MEDICAL
More informationTHE INHERENT CHALLENGES OF TESTING C. DIFFICILE
THE INHERENT CHALLENGES OF TESTING C. DIFFICILE Detecting Toxins Associated with C. difficile Infection Pritty Patel, MS, MBA, Global Director of Microbiology, Vaccines and Novel Immunotherapeutics, Covance
More informationLaboratory Diagnosis of Clostridium difficile Infections: There Is Light at the End of the Colon
INVITED ARTICLE CLINICAL PRACTICE Ellie J. C. Goldstein, Section Editor Laboratory Diagnosis of Clostridium difficile Infections: There Is Light at the End of the Colon Stephen M. Brecher, 1,2 Susan M.
More informationKerrie Eastwood, 1 Patrick Else, 1 André Charlett, 2 and Mark Wilcox 1 *
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2009, p. 3211 3217 Vol. 47, No. 10 0095-1137/09/$08.00 0 doi:10.1128/jcm.01082-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationComparison of nine commercially available C. difficile toxin detection assays, a real time
JCM Accepts, published online ahead of print on 26 August 29 J. Clin. Microbiol. doi:1.1128/jcm.182-9 Copyright 29, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More information/j x
REVIEW 10.1111/j.1469-0691.2009.03098.x European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI)
More informationon real time cell analysis system
JCM Accepts, published online ahead of print on August 00 J. Clin. Microbiol. doi:0./jcm.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationLoop-Mediated Isothermal Amplification Compared to Real-time PCR and Enzyme. Immunoassay for Toxigenic C. difficile Detection
JCM Accepts, published online ahead of print on 21 December 2011 J. Clin. Microbiol. doi:10.1128/jcm.01014-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Page 1 of 17 1 2 3
More informationCOMPARISON OF TWO CLOSTRIDIUM DIFFICILE TOXIN IMMUNOASSAYS AND A. REAL-TIME PCR ASSAY FOR C. DIFFICILE tcdc TO TOXIGENIC CULTURE FOR
COMPARISON OF TWO CLOSTRIDIUM DIFFICILE TOXIN IMMUNOASSAYS AND A REAL-TIME PCR ASSAY FOR C. DIFFICILE tcdc TO TOXIGENIC CULTURE FOR DETECTION OF TOXIN-PRODUCING C. DIFFICILE IN CLINICAL SAMPLES Trusha
More informationFigure S8. Two-way sensitivity analysis (cost-benefit model): symptomatic carrier proportion vs. lateral-flow GDH sensitivity
Documents included: Figure S1. Simplified decision tree model for lateral-flow GDH-Tox/odPCR Figure S2. Prisma diagram of included studies Figure S3. Forest plots of included studies Figure S4. One-way
More informationJoy Allen, William Jones, Michael Power, Stephen Rice, Greg Mantiapolous, Mark Wilcox, and Ashley Price
What is the potential for point of care diagnostics to improve testing protocols for C. difficile infection, with particular reference to the English NHS? Joy Allen, William Jones, Michael Power, Stephen
More informationComparison of two commercial molecular tests for the detection of Clostridium difficile in the routine diagnostic laboratory
Journal of Medical Microbiology (2011), 60, 1131 1136 DOI 10.1099/jmm.0.030163-0 Comparison of two commercial molecular tests for the detection of Clostridium difficile in the routine diagnostic laboratory
More informationCost and Impact on Patient Length of Stay of Rapid Molecular Testing for Clostridium difficile
Infect Dis Ther (2014) 3:281 293 DOI 10.1007/s40121-014-0034-x ORIGINAL RESEARCH Cost and Impact on Patient Length of Stay of Rapid Molecular Testing for Clostridium difficile Bernadette Sewell Eugene
More informationReceived 6 September 1994/Returned for modification 20 October 1994/Accepted 7 April 1995
JOURNAL OF CLINICAL MICROBIOLOGY, July 1995, p. 1755 1759 Vol. 33, No. 7 0095-1137/95/$04.00 0 Copyright 1995, American Society for Microbiology Concurrence of Clostridium difficile Toxin A Enzyme-Linked
More informationQuantStudio Dx Real-Time PCR Instrument
QuantStudio Dx Real-Time PCR Instrument Behind every diagnosis, there is a promise You believe in molecular medicine. So do we. We are committed to providing you with comprehensive solutions that help
More informationEvaluation of a New Commercial TaqMan PCR Assay for Direct Detection of the Clostridium difficile Toxin B Gene in Clinical Stool Specimens
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2009, p. 3846 3850 Vol. 47, No. 12 0095-1137/09/$12.00 doi:10.1128/jcm.01490-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Evaluation
More informationComparison of Real-Time PCR for Detection of the tcdc Gene with Four Toxin Immunoassays and Culture in Diagnosis of Clostridium difficile Infection
JOURNAL OF CLINICAL MICROBIOLOGY, June 2008, p. 1996 2001 Vol. 46, No. 6 0095-1137/08/$08.00 0 doi:10.1128/jcm.00032-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Comparison
More informationA New Rapid Method for Clostridium difficile DNA Extraction and Detection in Stool
A New Rapid Method for Clostridium difficile DNA Extraction and Detection in Stool Toward Point-of-Care Diagnostic Testing The Journal of Molecular Diagnostics, Vol. 14, No. 3, May 2012 Copyright 2012
More informationMICROBIOLOGY LETTERS. Discrepancies among three laboratory methods for Clostridium difficile detection and a proposal for their optimal use
RESEARCH LETTER Discrepancies among three laboratory methods for Clostridium difficile detection and a proposal for their optimal use Alexandre A. Monteiro 1, Renata N. Pires 1,2, Ludmila F. Baethgen 1,
More informationHow Do You Select a Gold Standard?
Cepheid report A Quarterly Publication by Cepheid How Do You Select a Gold Standard? Dealing with the Complexity of a Living Target No Test is Perfect Our Customers As Collaborators The Cepheid Healthcare
More informationCLINICAL SYMPTOMS AND RISK FACTORS TO REFINE PERFORMANCE CHARACTERISTICS OF LABORATORY ASSAYS FOR CLOSTRIDIUM DIFFICILE INFECTIONS
CLINICAL SYMPTOMS AND RISK FACTORS TO REFINE PERFORMANCE CHARACTERISTICS OF LABORATORY ASSAYS FOR CLOSTRIDIUM DIFFICILE INFECTIONS by Jaideep Mahesh Karamchandani B.A., Kalamazoo College, 2009 Submitted
More informationEvaluation of the rapid loop-mediated isothermal amplification assay Illumigene for diagnosis of Clostridium difficile in an outbreak situation
APMIS 122: 155 160 2013 The Authors. APMIS published by John Wiley & Sons Ltd. DOI 10.1111/apm.12121 Evaluation of the rapid loop-mediated isothermal amplification assay Illumigene for diagnosis of Clostridium
More informationIsolation of Clostridium difficile from faecal specimens a comparison of chromid C. difficile agar and cycloserine-cefoxitin-fructose agar
Journal of Medical Microbiology (), 6, 4 47 DOI.99/jmm..5655- Isolation of Clostridium difficile from faecal specimens a comparison of chromid C. difficile agar and cycloserine-cefoxitin-fructose agar
More informationClostridium difficile
Clostridium difficile By Karla Givens Means of Transmission and Usual Reservoirs Clostridium difficile or C. diff., is transmitted by oral contact with feces containing bacterial spores. Reservoirs include
More informationON-DEMAND. Outbreak! The New Clostridium difficile Basic Incidence and Testing Assumptions Called Into Question
CEPHEID ON-DEMAND REPORT A Quarterly Publication by Cepheid IN THIS ISSUE Volume 2, Issue 2 Cover Story: Outbreak! The New Clostridium difficile Inside: Vancomycin-Resistant Enterococci Still Here, Still
More informationBlood cultures: past, present and future. Dr Natalia Solomon MD, FRCPSC Medical Microbiologist DynaLIFE Dx
Blood cultures: past, present and future Dr Natalia Solomon MD, FRCPSC Medical Microbiologist DynaLIFE Dx Faculty/ Presenter Disclosure Faculty: Dr Natalia Solomon Relationships with commercial interests:
More informationi) Wild animals: Those animals that do not live under human supervision or control and do not have their phenotype selected by humans.
The OIE Validation Recommendations provide detailed information and examples in support of the OIE Validation Standard that is published as Chapter 1.1.6 of the Terrestrial Manual, or Chapter 1.1.2 of
More informationIf your name starts with a C, we are looking for you!!
Active surveillance for C. diff, CRE, (and Candida auris) in Houston If your name starts with a C, we are looking for you!! Kevin W. Garey, PharmD, MS, FASHP Professor and Chair Dept of Pharmacy Practice
More informationRIDA GENE Clostridium difficile LC2.0 real-time PCR
RIDA GENE Clostridium difficile LC2.0 real-time PCR Art. No.: PG0845 100 reactions For in vitro diagnostic use. -20 C R-Biopharm AG, An der neuen Bergstraße 17, D-64297 Darmstadt, Germany Tel.: +49 (0)
More informationon August 23, 2017 by guest
JCM Accepted Manuscript Posted Online 9 August 2017 J. Clin. Microbiol. doi:10.1128/jcm.00369-17 Copyright 2017 Mashock et al. This is an open-access article distributed under the terms of the Creative
More informationDisparate prevalence of toxigenic and nontoxigenic Clostridium difficile among distinct adult patient populations in a single institution
Journal of Medical Microbiology (2016), 65, 1237 1242 DOI 10.1099/jmm.0.000350 Disparate prevalence of toxigenic and nontoxigenic Clostridium difficile among distinct adult patient populations in a single
More informationRIDA QUICK Clostridium difficile GDH
RIDA QUICK Clostridium difficile GDH Product code: N0703 R-Biopharm AG, An der neuen Bergstraße 17, D-64297 Darmstadt, Germany Tel.: +49 (0) 61 51 81 02-0 / Fax: +49 (0) 61 51 81 02-20 C 1. Intended use
More informationEffects of Antibiotic Treatment on the Results of Nested ACCEPTED. Polymerase Chain Reactions for Scrub Typhus
JCM Accepts, published online ahead of print on 0 August 00 J. Clin. Microbiol. doi:0./jcm.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationQuarters 3-4, 2016 & Annual Data provisional 8 th March 2017
Version 1.0 Page 1 of 6 Invasive Pneumococcal Disease in Ireland Bi-annual report by the Health Protection Surveillance Centre Irish Pneumococcal Reference Laboratory, Temple Street Children s University
More informationMOLECULAR TESTING: VERIFYING/VALIDATING INSTRUMENTS, REAGENTS AND ASSAYS. Richard L. Hodinka, Ph.D.
MOLECULAR TESTING: VERIFYING/VALIDATING INSTRUMENTS, REAGENTS AND ASSAYS Richard L. Hodinka, Ph.D. University of South Carolina School of Medicine Greenville Greenville Health System, Greenville, SC hodinka@greenvillemed.sc.edu
More informationESCMID Online Lecture Library. by author
Edit Urbán Department of Clinical Microbiology Faculty of Medicine University of Szeged Hungary History Microbiology and ecology Epidemiology Transmisson Pathogenesis Clinical manifestations Diagnosis
More information1.0 Abstract. Palivizumab P Study Results Final
1.0 Abstract Title: Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
More informationNEXT STEP TO STOP THE SPREAD OF ANTIMICROBIAL RESISTANCE. Patricia Ruiz Garbajosa Servicio de Microbiología Hospital Universitario Ramón y Cajal
NEXT STEP TO STOP THE SPREAD OF ANTIMICROBIAL RESISTANCE Patricia Ruiz Garbajosa Servicio de Microbiología Hospital Universitario Ramón y Cajal ANTIMICROBIAL RESISTANCE AND HEALTHCARE-ASSOCIATED INFECTION
More informationType of intervention Primary prevention. Economic study type Cost-effectiveness analysis.
Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty Nerurkar J, Wade W E, Martin B C Record Status This is a critical abstract
More informationRIDA GENE Clostridium difficile real-time PCR
RIDA GENE Clostridium difficile real-time PCR Art. No.: PG0835 100 reactions For in vitro diagnostic use. -20 C R-Biopharm AG, An der neuen Bergstraße 17, D-64297 Darmstadt, Germany Tel.: +49 (0) 61 51
More informationHIMSS Davies Enterprise Application
HIMSS Davies Enterprise Application Applicant Organization: The Ohio State University Wexner Medical Center Organization s Address: 410 W 10 th Ave, Columbus, OH 43210 Submitter s Name: Kurt Stevenson,
More informationSuccessful performance in proficiency testing (PT) is required
Performance Characteristics of Several Rules for Self-interpretation of Proficiency Testing Data R. Neill Carey, PhD; George S. Cembrowski, MD; Carl C. Garber, PhD; Zohreh Zaki, MD Context. Proficiency
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/36395 holds various files of this Leiden University dissertation. Author: Knetsch, Cornelis Willem (Wilco) Title: Molecular typing & evolution of Clostridium
More informationClostridium difficile Update Dr. Michelle Alfa, Winnipeg Sponsored by ARJO
Clostridium difficile: Update Dr. Michelle Alfa Ph.D, FCCM Diagnostic Services of Manitoba St. Boniface General Hospital Site Hosted by Paul Webber paul@webbertraining.com Sponsored by www.arjo.com www.webbertraining.com
More informationABC. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. Volume 19 Number 18
M26-A ISBN 1-56238-384-1 September 1999 ISSN 0273-3099 Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline Volume 19 Number 18 Arthur L. Barry, Ph.D. William A. Craig,
More informationSCOTTISH Salmonella, Shigella & C.difficile REFERENCE LABORATORY (SSSCDRL)
SCOTTISH Salmonella, Shigella & C.difficile REFERENCE LABORATORY (SSSCDRL) Title User Manual LABORATORY PROCEDURE NUMBER / VERSION DATE OF ISSUE 15/09/2016 REVIEW INTERVAL AUTHORISED BY AUTHOR 2 Years
More informationFOCUS ON MRSA/SA SSTI ASSAY FAILURE IN PROSTHETIC JOINT. Institute of Microbiology, Lille University Hospital, F Lille, France
JCM Accepted Manuscript Posted Online 16 November 2016 J. Clin. Microbiol. doi:10.1128/jcm.01658-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. FOCUS ON MRSA/SA SSTI ASSAY FAILURE
More informationVersion 1.0v Page 1 of 5 Invasive Pneumococcal Disease in Ireland
Version 1.0v Page 1 of 5 Invasive Pneumococcal Disease in Ireland A Bi-annual report by the Health Protection Surveillance Centre and the Irish Pneumococcal Reference Laboratory at the Department of Clinical
More informationTechnical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products
Administrative Notice December 26, 2013 To: Division of Pharmaceutical Affairs, Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry
More informationSCOTTISH Salmonella, Shigella & C.difficile REFERENCE LABORATORY (SSSCDRL)
SCOTTISH Salmonella, Shigella & C.difficile REFERENCE LABORATORY (SSSCDRL) Title User Manual LABORATORY PROCEDURE NUMBER / VERSION SSSCDRL_UM_2017 DATE OF ISSUE 20/10/2017 REVIEW INTERVAL AUTHORISED BY
More informationBD MAX Extended Enteric Bacterial Panel (xebp)
BD MAX Extended Enteric Bacterial Panel (xebp) TABLE OF CONTENTS 1 Introduction 2 Product Overview 3 Benefits of the BD Solution 4 Summary WHY FOCUS ON ENTERIC TESTING? Typical workflow with conventional
More informationMicrobiology of Today and Tomorrow, How Changes in Technology will Impact the Care We Deliver
We Practice What We Teach Microbiology of Today and Tomorrow, How Changes in Technology will Impact the Care We Deliver Nathan A Ledeboer Associate Professor of Pathology Medical College of Wisconsin Medical
More informationSCOTTISH Salmonella, Shigella & C.difficile REFERENCE LABORATORY (SSSCDRL)
Title SCOTTISH Salmonella, Shigella & C.difficile REFERENCE LABORATORY (SSSCDRL) LABORATORY PROCEDURE NUMBER / VERSION User Manual DATE OF ISSUE 17/04/2014 REVIEW INTERVAL AUTHORISED BY AUTHOR 2 Years
More informationMay 9, Meeting Summary. Facilitating Antibacterial Drug Development
May 9, 2012 Meeting Summary Facilitating Antibacterial Drug Development Origins of the Current Public Health Crisis of Antibacterial Resistance Antibacterial drugs play a critical role in the ability to
More informationSynthetic Biologics Reports Year End 2012 Financial Results
April 16, 2013 Synthetic Biologics Reports Year End 2012 Financial Results -- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md.,
More informationE.coli O157:H7 Rapid Test (Card)
E.coli O157:H7 Rapid Test (Card) Cat. No.:DTS518 Pkg.Size: Intended use The E.coli O157:H7 Rapid Test is a one step coloured chromatographic immunoassay for the qualitative detection of Escherichia coli
More informationClostridium difficile TaqMan PCR Kit Product# TM37100
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Clostridium difficile TaqMan PCR Kit Product# TM37100 Product
More informationIDSA is pleased to offer the following comments on specific priority areas identified by FDA:
October 31, 2018 Shashi Malhotra Office of Acquisitions & Grants Services (OAGS) Food and Drug Administration Telephone: 240-402-7592 Email: Shashi.Malhotra@fda.hhs.gov SUBJECT: NOT-FD-18-16: Development
More informationPerformance of commercial enzyme-linked immunosorbent assays (ELISA) for diagnosis of HSV-1 and HSV-2 infection in a clinical setting
Performance of commercial enzyme-linked immunosorbent assays (ELISA) for diagnosis of HSV-1 and HSV-2 infection in a clinical setting Elfriede Ampong Agyemang A thesis submitted in partial fulfillment
More informationON-DEMAND. New England Baptist Hospital: Testing Patients for MRSA and Staph aureus Before Inpatient Surgery
CEPHEID ON-DEMAND REPORT A Quarterly Publication by Cepheid Volume 1, Issue 2 IN THIS ISSUE Cover Story: New England Baptist Hospital: Testing Patients for MRSA and Staph aureus Before Inpatient Surgery
More informationA new type of toxin A-negative, toxin B-positive Clostridium difficile strain
JCM Accepts, published online ahead of print on 26 November 2014 J. Clin. Microbiol. doi:10.1128/jcm.02211-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 A new type of toxin
More informationoriginal article The value of repeat Clostridium difficile toxin testing during and after an outbreak of C difficile-associated diarrhea
original article The value of repeat Clostridium difficile toxin testing during and after an outbreak of C difficile-associated diarrhea Joseph Dylewski MD J Dylewski. The value of repeat Clostridium difficile
More informationRenate J. van den Berg, 1 Norbert Vaessen, 1 Hubert P. Endtz, 2 Tanja Schülin, 3 Eric R. van der Vorm 4 3 and Ed J. Kuijper 1 INTRODUCTION
Journal of Medical Microbiology (2007), 56, 36 42 DOI 10.1099/jmm.0.46680-0 Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea
More informationENCEPP CONSIDERATIONS ON THE DEFINITION OF NON-INTERVENTIONAL TRIALS UNDER THE CURRENT LEGISLATIVE FRAMEWORK ( CLINICAL TRIALS DIRECTIVE 2001/20/EC)
ENCEPP CONSIDERATIONS ON THE DEFINITION OF NON-INTERVENTIONAL TRIALS UNDER THE CURRENT LEGISLATIVE FRAMEWORK ( CLINICAL TRIALS DIRECTIVE 2001/20/EC) Agreed by the European Network of Centres for Pharmacoepidemiology
More informationInterim Technical Note The Use of Cholera Rapid Diagnostic Tests November 2016
Objective Interim Technical Note The Use of Cholera Rapid Diagnostic Tests November 2016 To provide interim guidance to Ministries of Health and other organizations on the potential use of commercially
More informationWelsh Healthcare Associated Infection Programme (WHAIP)
Surveillance: Report: Clostridium difficile Surveillance Time period: 2012 Health Board: All Wales Content: Pg 1 Summary Pg 2 Introduction Pg 3 Methods Results Pg 4 PCR Ribotyping Results Pg Antimicrobial
More informationTake Home Exam Example 1: Determining the role of the novel compound WD6 in Clostridium difficile toxin A and B regulation.
Take Home Exam Example 1: Determining the role of the novel compound WD6 in Clostridium difficile toxin A and B regulation. Microbial Pathogenesis MMIC 7050 Clostridium difficile is a Gram positive anaerobic
More informationPOET REPORT Perspectives on Emerging Technology
POET REPORT Perspectives on Emerging Technology In Vitro Diagnostic Multivariate Assays (IVDMIAs) September, 2009 Developed by the CAP s Technology Assessment Committee College of American Pathologists
More informationCHAPTER 24. Immunology
CHAPTER 24 Diagnostic i Microbiology and Immunology Growth-Dependent Diagnostic Methods Isolation of Pathogens from Clinical Specimens Proper sampling and culture of a suspected pathogen is the most reliable
More informationUPDATE. Laboratory diagnosis of Clostridium difficile disease. M. Delmée. Microbiology Unit, Université Catholique de Louvain, Brussels, Belgium
UPDATE Laboratory diagnosis of Clostridium difficile disease M. Delmée Microbiology Unit, Université Catholique de Louvain, Brussels, Belgium The laboratory diagnosis of Clostridium difficile-associated
More informationVAE Questions and Case Studies
VAE Questions and Case Studies Cindy Gross, MT, SM (ASCP), CIC IP Consultant April 30, 2014 National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion Review
More informationAnna Tousseeva J. Derek Jackson Mark Redell Teresa Henry Michael Hui Shelley Capurso C. Andrew DeRyke
Drugs R D (2014) 14:309 314 DOI 10.1007/s40268-014-0067-3 ORIGINAL RESEARCH ARTICLE Stability and Recovery of DIFICID Ò (Fidaxomicin) 200-mg Crushed Tablet Preparations from Three Delivery Vehicles, and
More informationVerification of Environmental Cleaning & the Impact on Patient Safety
SM 3M Health Care Academy Verification of Environmental Cleaning & the Impact on Patient Safety July 20, 2016 Steve Zeplin, RN, MSN, CSPDT House Keeping Continuing Education Each 1 hour web meeting qualifies
More informationThorny topics related to CRE control
Thorny topics related to CRE control Michael Lin, MD MPH Rush University Medical Center Chicago CDC Prevention Epicenter 19 th Annual Chicago Infection Control Conference May 30, 2014 Disclosures I have
More informationIdentifying Clostridium Difficile in the ICU Using Bayesian Networks
Identifying Clostridium Difficile in the ICU Using Bayesian Networks Phenome Based Analysis Peijin Zhang Second Annual MIT PRIMES Conference May 20th, 2012 MIT Primes Conference - Peijin Zhang 1 of 21
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationComparison of ChromID Agar and Clostridium difficile Selective Agar for Effective Isolation of C. difficile from Stool Specimens
Original Article Clinical Microbiology Ann Lab Med 2014;34:15-19 http://dx.doi.org/10.3343/alm.2014.34.1.15 ISSN 2234-3806 eissn 2234-3814 Comparison of ChromID Agar and Clostridium difficile Selective
More informationA Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Clostridium difficile
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Clostridium difficile vaccine administered with or without Aluminum Hydroxide, in a 3-Dose Regimen in Healthy Adults Aged 50
More information16S rdna Sequencing Diagnosis of Spirochetemia in Lyme and related Borrelioses
16S rdna Sequencing Diagnosis of Spirochetemia in Lyme and related Borrelioses Sin Hang Lee, MD, F.R.C.P.(C)* Pathologist, Milford Hospital and Director, Milford Medical Laboratory, Inc. Milford, CT Email:
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationCorrespondence should be addressed to Tavan Janvilisri;
BioMed Volume 2013, Article ID 875437, 6 pages http://dx.doi.org/10.1155/2013/875437 Research Article Evaluation of Multiplex PCR with Enhanced Spore Germination for Detection of Clostridium difficile
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/36395 holds various files of this Leiden University dissertation. Author: Knetsch, Cornelis Willem (Wilco) Title: Molecular typing & evolution of Clostridium
More informationDepartment of Laboratory Medicine and Genetics, Sungkyunkwan University School of Medicine, Seoul, Korea
Original Article Clinical Microbiology Ann Lab Med 2015;35:404-409 http://dx.doi.org/10.3343/alm.2015.35.4.404 ISSN 2234-3806 eissn 2234-3814 Isolation and Identification of Clostridium difficile Using
More informationEconomic evaluation of zinc and copper use in treating acute diarrhea in children: a randomized controlled trial Patel A B, Dhande L A, Rawat M S
Economic evaluation of zinc and copper use in treating acute diarrhea in children: a randomized controlled trial Patel A B, Dhande L A, Rawat M S Record Status This is a critical abstract of an economic
More informationPREQUALIFICATION OF IN VITRO DIAGNOSTICS
Prequalification-In vitro Diagnostics Assessment PREQUALIFICATION OF IN VITRO DIAGNOSTICS WHO PROTOCOL FOR THE PERFORMANCE EVALUATION OF RAPID DIAGNOSTIC TESTS FOR DETECTION OF VIBRIO CHOLERAE LPS ANTIGEN
More informationPrepared by Date Adopted Supersedes Procedure # Adapted from HPTN Policy. Review Date Revision Date Signature
APPENDIX IV: LABORATORY QUALITY CONTROL POLICY Prepared by Date Adopted Supersedes Procedure # Adapted from HPTN Policy N/A Review Date Revision Date Signature Distributed to # of Copies Distributed to
More informationESCMID Online Lecture Library. Molecular diagnosis of malaria. by author
Molecular diagnosis of DNA malaria Aldert Bart Parasitology Medical Microbiology Academic Medical Center Amsterdam ESCMID course 05-06-12 Putative advantages of molecular diagnosis of malaria correct (unequivocal?)
More informationTrends in Chronologic Age and Infant Respiratory Syncytial Virus Hospitalization: an 8-Year Cohort Study
Adv Ther (2011) 28(3):195-201. DOI 10.1007/s12325-010-0106-6 ORIGINAL RESEARCH Trends in Chronologic Age and Infant Respiratory Syncytial Virus Hospitalization: an 8-Year Cohort Study Jon P. Fryzek William
More informationRunning title: Verigene C. difficile Assay. Weissfeld, Ph.D 8, Nathan A. Ledeboer 3
JCM Accepts, published online ahead of print on 2 October 2013 J. Clin. Microbiol. doi:10.1128/jcm.01690-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationThe CDC big three; challenges from the laboratory perspective. Todd F Hatchette MD FRCPC AMMI Annual Conference 2015 Charlottetown, PEI
The CDC big three; challenges from the laboratory perspective Todd F Hatchette MD FRCPC AMMI Annual Conference 2015 Charlottetown, PEI Disclosures PHAC working groups Department of Health and Wellness
More informationIGRAs for Serial Testing of Healthcare Workers
IGRAs for Serial Testing of Healthcare Workers Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding
More informationGUIDANCE FOR INTERPRETATION OF PCR ASSAYS FOR VEROCYTOTOXIGENIC
GUIDANCE FOR INTERPRETATION OF PCR ASSAYS FOR VEROCYTOTOXIGENIC E COLI: FOR HEALTH PROTECTION TEAMS AND MICROBIOLOGISTS 1. Purpose of this document The purpose of this document is to provide broad recommendations
More informationBringing True Novelty to the Anti-Infective Space
Bringing True Novelty to the Anti-Infective Space New Class of Antibacterials Based on a Unique Mechanism of Action Dr Dawn Firmin SMi s 17 th Annual Conference on Superbugs & Superdrugs March 2015 1 Contents
More informationAssessing quality-assured diagnoses made by TB laboratories
Assessing quality-assured diagnoses made by TB laboratories Quality-assured TB laboratory Objectives: at the end of the assessment reviewers should comment on the laboratory network and its structure;
More informationGenMark Diagnostics TRANSFORMING MULTIPLEX MOLECULAR TESTING. J.P. Morgan Healthcare Conference 2019
GenMark Diagnostics TRANSFORMING MULTIPLEX MOLECULAR TESTING J.P. Morgan Healthcare Conference 2019 1 Forward-Looking Statements This presentation contains forward-looking statements about GenMark Diagnostics,
More informationMicrobiology of Healthcare-associated Infections
Microbiology of Healthcare-associated Infections William A. Rutala, Ph.D., M.P.H. Director, Statewide Program for Infection Control and Epidemiology and Professor of Medicine, University of North Carolina
More informationInnovations in Molecular Lab Operation. Joseph M. Campos, PhD, D(ABMM), F(AAM)
Innovations in Molecular Lab Operation Lessons in the Best Ways to Blend Automation, Lean Workflow, and Paperless Processes Joseph M. Campos, PhD, D(ABMM), F(AAM) Interim Chief, Division of Laboratory
More information